CTLA4 and melanoma: The earliest reports that CD4+ T cells could be directly cytotoxic to patient tumor cells involved isolation of circulating CD4+ T cell clones specific for NY-ESO-1 in melanoma patients treated with ipilimumab (anti-CTLA-4).